Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Jazz Pharmaceuticals plc JAZZ

Healthcare
Jazz Pharmaceuticals PLC is a biotechnology company. The Company is engaged in developing medicines for people with serious diseases. The Company’s lead marketed products include Xywav (calcium, magnesium, potassium, and sodium oxybates) oral solution, Xyrem (sodium oxybate) oral solution, Epidiolex (cannabidiol) oral solution, Rylaze (asparaginase erwinia chrysanthemi (recombinant)-rywn... see more

Recent & Breaking News (NDAQ:JAZZ)

Jazz Pharmaceuticals Announces Share Repurchase Program Authorization Increase of $400 Million

PR Newswire December 10, 2018

Report: Exploring Fundamental Drivers Behind Jazz Pharmaceuticals, 58, Encore Capital Group, Churchill Downs, Addus HomeCare, and Huntington Ingalls Industries — New Horizons, Emerging Trends, and Upcoming Developments

GlobeNewswire November 29, 2018

Jazz Pharmaceuticals Announces First Patient Enrolled in Phase 3 Clinical Trial Evaluating JZP-258 for the Treatment of Idiopathic Hypersomnia

PR Newswire Europe Non Regulatory November 29, 2018

Jazz Pharmaceuticals to Highlight Hematology Research at ASH 2018 Annual Meeting

PR Newswire Europe Non Regulatory November 28, 2018

Jazz Pharmaceuticals Submits Marketing Authorization Application to European Medicines Agency for Solriamfetol as a Treatment to Improve Wakefulness and Reduce Excessive Daytime Sleepiness in Adult Patients with Narcolepsy or Obstructive Sleep Apnea

PR Newswire Europe Non Regulatory November 9, 2018

National Institute for Health and Care Excellence (NICE) Recommends Jazz Pharmaceuticals' Vyxeos® (Daunorubicin and Cytarabine) for Adults with Specific Types of Secondary Acute Myeloid Leukaemia (AML)

PR Newswire November 7, 2018

Jazz Pharmaceuticals Announces Participation at Upcoming Investor Conferences

PR Newswire Europe Non Regulatory November 7, 2018

Jazz Pharmaceuticals Announces Third Quarter 2018 Financial Results

PR Newswire November 6, 2018

Jazz Pharmaceuticals Announces FDA Approval of Xyrem® (sodium oxybate) for the Treatment of Cataplexy or Excessive Daytime Sleepiness in Pediatric Narcolepsy Patients

PR Newswire Europe Non Regulatory October 29, 2018

Jazz Pharmaceuticals to Report 2018 Third Quarter Financial Results on November 6, 2018

PR Newswire Europe Non Regulatory October 23, 2018

Detailed Research: Economic Perspectives on W.W. Grainger, Jabil, Grand Canyon Education, Sage Therapeutics, H. B. Fuller, and Jazz Pharmaceuticals — What Drives Growth in Today's Competitive Landscape

GlobeNewswire October 19, 2018

Jazz Pharmaceuticals Survey Highlights Significant Impact of Excessive Daytime Sleepiness Related to Sleep Apnea

PR Newswire October 10, 2018

Attention Biotech Investors: Mark Your Calendar For These October PDUFA Dates

Benzinga.com  September 26, 2018

Jazz Pharmaceuticals Announces an Informational Webcast for Investors Related to Vyxeos EU Launch

PR Newswire Europe Non Regulatory September 11, 2018

Jazz Pharmaceuticals Announces Participation in Two Upcoming Investor Conferences

PR Newswire August 29, 2018

Vyxeos® Receives Marketing Authorisation in the European Union for Treatment of Certain Types of High-Risk Acute Myeloid Leukaemia

PR Newswire Europe Non Regulatory August 27, 2018

Jazz Pharmaceuticals Announces Second Quarter 2018 Financial Results

PR Newswire Europe Non Regulatory August 7, 2018

Jazz Pharmaceuticals and MD Anderson Cancer Center Collaborate to Evaluate Potential Treatment Options for Hematologic Malignancies

PR Newswire Europe Non Regulatory August 6, 2018

CMS Grants New Technology Add-On Payment to Vyxeos® (daunorubicin and cytarabine) Liposome for Injection

PR Newswire Europe Non Regulatory August 3, 2018

Jazz Pharmaceuticals to Report 2018 Second Quarter Financial Results on August 7, 2018

PR Newswire Europe Non Regulatory July 24, 2018